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Abstract
Background: Despite long-lasting HIV replication control, a significant proportion of elite controller (EC) patients
may experience CD4 T-cell loss. Discovering perturbations in immunological parameters could help our
understanding of the mechanisms that may be operating in those patients experiencing loss of immunological
control.
Methods: A case–control study was performed to evaluate if alterations in different T-cell homeostatic parameters
can predict CD4 T-cell loss in ECs by comparing data from EC patients showing significant CD4 decline (cases) and
EC patients showing stable CD4 counts (controls). The partial least-squares–class modeling (PLS-CM) statistical
methodology was employed to discriminate between the two groups of patients, and as a predictive model.
Results: Herein, we show that among T-cell homeostatic alterations, lower levels of naïve and recent thymic
emigrant subsets of CD8 cells and higher levels of effector and senescent subsets of CD8 cells as well as higher
levels of exhaustion of CD4 cells, measured prior to CD4 T-cell loss, predict the loss of immunological control.
Conclusions: These data indicate that the parameters of T-cell homeostasis may identify those EC patients with a
higher proclivity to CD4 T-cell loss. Our results may open new avenues for understanding the mechanisms
underlying immunological progression despite HIV replication control, and eventually, for finding a functional cure
through immune-based clinical trials.
Keywords: Elite controllers, CD4 T-cell loss, Class modeling, T-cell homeostatic parameters, CD8 exhaustion
Background
Human immunodeficiency virus-1 (HIV-1) infection is
mostly characterized by ongoing viral replication leading
to a progressive decline of CD4+ T cells and eventually
progression to clinical AIDS. Nevertheless, there is a
small subset of HIV-1+ subjects who are able to spon-
taneously control HIV-RNA replication in plasma to
levels below the limit of detection in the absence of
antiretroviral therapy. They are called elite controllers
(ECs) and represent less than 1% of the total of HIV-
infected patients [1]. ECs have been considered as a
model of spontaneous functional cure and the role of
host genetic factors, innate and adaptive immune re-
sponses, viral characteristics, and their interactions have
been analyzed in several studies [1–5].
However, ECs constitute a heterogeneous group in
terms of genetic and immunologic characteristics [6],
and no single mechanism has been described as being
responsible for controlling viral replication [5–7]. These
patients are also heterogeneous from the clinical point
of view, since some of them show either virologic and/or
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cohorts of EC patients have reported that as many as 25%
of them experience virological progression (losing the abil-
ity to maintain HIV replication control) [11], and around
20% experience immunological progression (a decline in
CD4 counts) even in the absence of virological progres-
sion [8, 9], as we have also previously demonstrated in our
cohort of HIV controllers of the Spanish AIDS Research
Network (the ECRIS cohort) [11]. However, the mecha-
nisms accounting for this CD4 T-cell loss in ECs remain
largely unknown.
Given the relevance of different alterations of T-cell
homeostasis in the CD4 depletion observed in HIV patients
with uncontrolled viral replication [12–14], some of these
same mechanisms might be operating in EC patients ex-
periencing CD4 T-cell loss. In this regard, previous studies
have shown that even though EC patients are able to sup-
press HIV replication to an undetectable level, they present
different T-cell homeostasis disturbances compared to
uninfected controls and/or to HIV non-controllers with
suppression of HIV replication mediated by combination
antiretroviral therapy (cART) [15–20], suggesting that T-
cell homeostasis disturbances are still operating in EC pa-
tients and could potentially be involved in the immuno-
logical progression.
To test this hypothesis, and with the final aim of find-
ing predictors of immunological progression, herein we
have comprehensively compared several important
parameters of T-cell homeostasis in EC patients with
long-lasting HIV replication control but experiencing
immunological progression with those for EC patients
showing no progression. The partial least-squares–class
modeling (PLS-CM) methodology was applied as a stat-
istical modeling technique to discriminate between the
two groups of patients, and as a predictive model.
Methods
Study population
This is a case–control study including adult patients
with chronic HIV infection and with long-term spontan-
eous control of HIV replication (EC patients) during the
whole study follow-up period, recruited from the cohort
of HIV controllers of the Spanish AIDS Research
Network (ECRIS cohort) launched in 2013. ECRIS is an
open multicenter cohort of HIV controller patients. The
data are from the Spanish Long-Term Non-Progressors
(LTNP) cohort and the Spanish AIDS Research Network
(CoRIS) cohort [21], and from different clinical centers
in Spain. To be included in the ECRIS cohort, EC
patients were defined as asymptomatic individuals with
at least three consecutive plasma HIV viral load (pVL)
determinations below the detection limit (pVL < 50
copies/mL) during at least 12 months of follow-up, in
the absence of any cART. The characteristics of the
ECRIS cohort have been described in detail elsewhere
[11]. Only those EC subjects maintaining long-term con-
trol of HIV replication (more than 3 years) with regular
immunovirological follow-ups (CD4 counts and pVL)
and with available baseline cryopreserved cellular sam-
ples were included in the study. Baseline was the begin-
ning of the follow-up period as an EC patient.
Selection of EC study groups
The relevant CD4 data for each patient were measured
during the follow-up period if the patient maintained
their EC status. All of these data were used in a linear
regression analysis to estimate the CD4 slope for the pa-
tient. According to the CD4 slope, the study population
was categorized into two groups: EC controls, patients
with stable CD4 counts during the follow-up period
(CD4 count slope not significantly different from zero)
and EC cases, patients whose CD4 counts declined dur-
ing the follow-up period (a statistically significant and
negative CD4 count slope). A total of 36 EC patients
were included: 22 being EC controls and 14 being EC
cases (Additional file 1 and Fig. 1). Moreover, 14 age-
and sex-matched healthy controls (HIV-uninfected indi-
viduals) were included as a healthy control group (HCs).
Cell samples
Anonymized samples from both groups of patients were
kindly provided by the HIV BioBank, which is integrated
into the Spanish AIDS Research Network (RIS) [22].
Anonymized data were taken from the ECRIS cohort
database (see Additional file 1), according to the sample
assignment agreement reference 19/15 dated 25 August
2015. All analyses were done with cryopreserved periph-
eral blood mononuclear cells (PBMCs), and were
performed when both groups of EC patients (cases and
controls) presented similar levels of CD4 counts, that is
prior to CD4 T-cell loss in EC cases. EDTA-anticoagulated
blood was obtained by venipuncture. PBMCs were immedi-
ately isolated by density gradient centrifugation using
Ficoll-Hypaque (Sigma Chemical Co., St. Louis, MO), fro-
zen in fetal calf serum plus 10% dimethyl sulfoxide, and
stored in liquid nitrogen in the Spanish AIDS Research
Network HIV BioBank. The viability of thawed PBMCs was
always greater than 85%.
Immunophenotypic analysis
We used a comprehensive approach of simultaneously meas-
uring different T-cell parameters involved in HIV pathogen-
esis: differentiation stage; recent thymic emigrants (RTEs);
activation, exhaustion, and apoptosis of T memory stem cells
(Tscm cells); T regulatory cells (Treg cells); replicative senes-
cence; and response to homeostatic cytokines. We selected a
total of 16 different monoclonal antibodies distributed in two
different panels of 11 and 13 antibodies (plus a cell viability
marker), which in combination defined 350 different
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unique T-cell subsets that were analyzed by multi-
parametric flow cytometry. A complete list of all
monoclonal antibodies and fluorochromes used in the
study as well as antibodies included in each of the
two staining panels is shown in Additional file 2. A
minimum of 2 million of PBMCs from each patient
were stained with each antibody panel, and a detailed
description of staining conditions and definitions of
T-cell subsets analyzed is given in Additional file 3.
Statistical analyses
The main characteristics of the study population and the
different parameters evaluated are expressed as median
and interquartile range. Comparisons between groups
were done using a Mann–Whitney U test. The two-
tailed p values were considered as significant only when
they were lower than 0.05. All statistical analyses were
performed using the SPSS software version 15 (SPSS
Inc., Chicago, IL, USA). PLS-CM was employed to
discriminate between the different groups of subjects
included in the study (control patients, case patients,
and HCs). Two PLS models were generated: one to
discriminate between EC patients and HCs (PLS-1) and
another to discriminate between cases and control
groups of EC patients (PLS-2). In these models, 350 im-
munological parameters were used as predictor (explica-
tive) variables of the model, and the subjects’ group was
the predicted (response) binary variable. For PLS-1, a
value of 0 was assigned to EC patients and a value of 1
was assigned to HCs. For PLS-2, a value of 0 was
assigned to EC controls and a value of 1 to EC cases.
In the first step, PLS was used to select a minimum
set of predictor variable to reduce the original 350 im-
munological variables to simplify the analysis without
losing any information. The parameter employed to
make this selection, called variable influence on projec-
tion (VIP), summarizes the importance of the predictor
variable on the model taking into account the amount of
explained variance of the predicted (response) variable.
In the second step, a PLS model was built using the
selected set of predictor variables grouped together to
generate a minimum set of latent variables (LVs) that are
not directly observed (measured) but rather inferred
(through a mathematical model) from other variables
that are observed (directly measured). Each LV is a
linear combination of the original set of observable vari-
ables. A clear advantage of using LVs is that it reduces
the dimensionality of data. The number of LVs included
in the PLS model is optimized to maximize the
explained variance of the X (predictor variables) and Y
(response variable) components of the model. Applying
this PLS model, a predicted value for the response vari-
able was estimated for each sample and for these pre-
dicted values, a probability distribution was generated.
For this distribution, the probabilities α and ß for type I
and II errors of the hypothesis test, respectively, were
calculated. The sensitivity [(1- α) × 100] and specificity
[(1- ß) × 100] of the PLS model were used to assign each
sample to its correct group. A detailed explanation of
PLS-CM is given in Additional file 4.
Results
Patient characteristics
The CD4 slope during the follow-up period for controls
and cases is shown in Table 1. Of the 36 EC patients in-
cluded in the study, 22 were considered controls (stable
CD4 counts during the follow-up period) and 14 were
considered cases (significant CD4 decline during the
follow-up period). All immunological parameters were
measured prior to CD4 T-cell loss in EC cases. The
evolution of CD4 counts during the follow-up period for
controls and cases is shown in Fig. 1. The main charac-
teristics of the controls and cases are shown in Table 1.
There were no significant differences between control
and case groups in terms of age, median time since diag-
nosis, CD4 count at the beginning of follow-up, CD4
count at the commencement of the study, percentage of
patients infected with hepatitis C virus, percentage of
Fig. 1 Scatterplots showing the evolution of the CD4 count during the follow-up period for two groups of EC patients: those showing stable
CD4 counts (left) and those showing a significant CD4 decline (right). Each individual line represents data from one patient. EC elite controller
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patients presenting with non-AIDS defining events dur-
ing the follow-up period, and number of HIV-RNA blips
during the follow-up period.
PLS class modeling of EC patients versus HC subjects
(PLS-1)
First a PLS model was generated to discriminate be-
tween EC patients and HIV-seronegative HC subjects. A
data matrix with 50 samples (36 EC patients and 14
HCs) and 350 variables was used to fit a first PLS model
without any data preprocessing. A binary variable took
the value 0 if the sample was from an EC patient and 1
if it was from a HC. This model let us choose 93 vari-
ables with VIP values higher than 1 so that we could
simplify the analysis without losing any information. A
new PLS model (PLS-1) with the same criteria and a re-
duced data matrix with 93 variables was built. Three LVs
were included in the final PLS model, and the percent-
age of explained variance of the response variable (y)
and predictor variables (X) is shown in Table 2 for PLS-
1. A normal distribution for each class (EC patients and
HCs) was fitted with the values of the response variable
calculated by the PLS model because the p values of the
normality tests were greater than 0.1. These density
functions for each class are plotted in Fig. 2. The mean
and standard deviation of the calculated response vari-
able for the PLS-1 model for the EC patient and HC
classes are, respectively, 0.075 ± 0.219 and 0.810 ± 0.146
(Fig. 2).
By choosing a threshold to differentiate between EC
patients and HC subjects, we can see in Fig. 2 that the
small area under the density function of the class of EC
patients on the right of the threshold is the probability α
of rejecting the null hypothesis (H0: the sample belongs
to the EC patient class) when it is true. On the other
hand, the small area under the density function of the
class of HCs on the left of the threshold is the probabil-
ity β of accepting the null hypothesis (H0) when it is
false. By changing the threshold, a risk curve of type α
error versus type ß error can be generated and from this
we can estimate the pair of equal values of sensitivity
[(1-α) × 100] and specificity [(1- ß) × 100] of the model
(Fig. 3). For the PLS-1 model, these values were both
98%. To visualize the ability of the PLS model to dis-
criminate between EC patients and HCs, Fig. 4 (left)
shows the projection in a plane of the scores for LV2
and LV3 (rotated 25° counterclockwise) for each of the
50 individuals of the study (36 EC patients and 14 HCs).
Table 1 Characteristics of patients included in the study
Characteristic Control group (n = 22) Case group (n = 14) p value
Age (years)a 40 [35, 48] 42 [39, 48] 0.58
Gender (% of males) 33 69 0.04
Follow-up maintaining EC status (years) 12 [10, 13] 9 [5, 12] 0.02
Time since HIV diagnosis (years) 19.3 [14.8, 24.1] 19.3 [9.6, 21.8] 0.62
CD4 count at the beginning of follow-up (cells/μL) 838 [646, 1097] 1047 [881, 1125] 0.06
CD4 count at the end of follow-up (cells/μL) 931 [675, 1147] 632 [443, 843] 0.01
CD4 slope (cells/μL per year) 8.9 [1.2, 19] -66 [− 113, −32] < 0.0001
CD4 count at the moment of the study (cells/μL) 889 [752, 1051] 886 [548, 1280] 0.87
Hepatitis C virus positive (%) 80 69 0.68
Patients with non-AIDS defining events during the follow-up period (%) 11 11 1
Number of HIV-RNA blips (pVL > 50 copies/mL) 2 [0, 2.3] 1 [0, 2.3] 0.43
EC elite controller
aData for continuous variables are given as median [interquartile range]
Table 2 Percentage of variance of predictor (X block) and response (y block) variables explained by the PLS models. Individual






X block y block X block y block
Partial Total Partial Total Partial Total Partial Total
1 91.4 91.4 31.6 31.6 1 92.1 92.1 38.1 38.1
2 1.4 92.8 43.3 74.9 2 1.4 93.5 26.2 64.3
3 1.1 93.9 6.1 81.0 3 0.8 94.3 16.9 81.2
4 0.7 95.0 3.4 84.6
Numbers in bold represent the total variance explained by the PLS model
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This plot has a vertical line (a rotated LV2 value) that
perfectly separates EC patients (on the left) and HC sub-
jects (on the right).
PLS class modeling of EC cases versus EC controls (PLS-2)
PLS class modeling was applied to discriminate between
EC cases (EC patients showing a CD4 decline during the
follow-up period) and EC controls (EC patients with
stable CD4 counts during the follow-up period). Firstly,
by fitting a PLS model with samples from 36 patients
(22 EC controls and 14 EC cases), 77 variables from the
350 original ones with a VIP value higher than 1 were
selected. No data preprocessing was used and a binary
response variable took the value 0 if the sample was
from an EC control and the value 1 if it was from an EC
case. The same procedure as used for PLS-1 was
followed.
A PLS regression (PLS-2) with the same previous cri-
teria and the reduced data matrix with 77 variables was
built with four LVs. The percentages of explained vari-
ance by the model of the X and y variables are shown in
Table 2 (under PLS-2). We checked that the p values of
the normality tests were greater than 0.10 and therefore,
a normal distribution for each class (EC cases and EC
controls) was fitted with the values of the response vari-
able calculated by the PLS model. The normal density
functions for each class were plotted (Fig. 2). The mean
values and standard deviation of the response variable
calculated by the PLS model for the EC case and EC
control classes were respectively 0.096 ± 0.247 and 0.846
± 0.162 (Fig. 2).
By changing the threshold, a risk curve of type α versus
type ß errors was generated and from this we estimated
the pair of equal values of sensitivity [(1-α) × 100] and
specificity [(1- ß) × 100] of the model (Fig. 3). For the
PLS-2 model, these values were both 97%. To visualize
the ability of the PLS-2 model to discriminate between EC
cases and EC controls, Fig. 4 shows the projection in a
plane of the scores for LV2 and LV3 rotated 49° counter-
clockwise. This plot shows has a vertical line (a rotated
LV2 value) that perfectly separates EC controls (on the
left) and EC cases (on the right).
The PLS model shows that the immunological vari-
ables have information with sufficient specificity and
sensitivity to discriminate between the EC controls and
the EC cases (this is also true for discriminating between
Fig. 2 Density functions for values calculated by models PLS-1 (left) and PLS-2 (right) for the two classes of individuals: EC patients and HC sub-
jects for the PLS-1 model, and EC cases and EC controls for the PLS-2 model. The vertical line represents a threshold value chosen to differentiate
between the classes. The small overlapping areas to the right and to the left of this line represent the probabilities α and β, respectively. EC elite
controller, HC healthy control
Fig. 3 Risk curves ß versus α for the PLS-1 (left) and PLS-2 (right) class models. Different pairs of α and ß are marked as black squares. The pair of
equal values of sensitivity and specificity is shown. EC elite controller, HC healthy control
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EC patients and HC subjects). There is an underlying
structure responsible for this capacity of discrimination
that is reducible to two LVs. However, the immuno-
logical variables are all on the same scale (percentage)
and it is not appropriate to normalize them since the
variables that are noise in the discrimination acquire the
same magnitude as those truly responsible for it and
may be incorrectly included in the model. The conse-
quence of not normalizing the data is twofold: (1) one of
the LVs is linked to the distance between the vector
formed by the mean values of the predictor variables
and the origin of coordinates and (2) the immunological
variables with a smaller range may not be selected due
to a numerical effect. In addition, PLS tends to eliminate
highly correlated variables because they do not carry in-
dependent information, although their immunological
meaning may be relevant and different. Consequently,
choosing the immunological variables for which the dif-
ference between classes is perceived is done by evaluat-
ing the individual distribution of their values, as in the
Mann–Whitney U test.
T-cell parameters significantly altered in EC patients with
respect to healthy subjects
Of the 93 immunological variables selected by the PLS-1
model to differentiate EC patients from healthy subjects,
43 presented statistically significant differences when EC
patients and healthy subjects were compared with the
Mann–Whitney test. Since the immunological variables
are all on the same scale and it is not appropriate to
normalize them, the PLS-CM model did not normalize
the variables, and for this reason the immunological var-
iables with a smaller range may not have been selected.
Nevertheless, those variables could have some relevant
information. Thus, using the Mann–Whitney U test, it
was possible to evaluate those variables significantly dif-
ferent between EC patients and healthy subjects but that
were not selected by the PLS model. In fact, there were
another 36 immunological variables significantly differ-
ent between EC patients and healthy subjects that were
not selected by the PLS model due to a numerical effect.
A complete list of immunological variables with signifi-
cant differences is shown in Additional file 5.
Figure 5 shows levels for the most relevant variables in
EC patients and healthy subjects. Among CD4 T-cell sub-
sets, EC patients showed lower levels of Tscm and Treg
subsets and higher levels of the CD45RA-CD27-CCR7-
subset compared to healthy subjects. Interestingly, expres-
sion of activation marker CD38 (but not of HLADR) was
also lower in total CD4 T cells and in naïve CD4 T cells of
EC patients. In contrast, co-expression of activation
markers CD38 and HLADR was higher in Tscm cells of EC
patients. The proportion of naïve CD4 cells lacking expres-
sion of CD28 was also higher in EC patients.
Among CD8 T-cell subsets, EC patients showed lower
levels of naïve RTE (naïve cells expressing CD31) and
Tscm subsets compared to healthy subjects. However,
co-expression of activation markers CD38 and HLADR
in total CD8+ cells and in effector (CD45RA + CD27-
CCR7-) subset was higher in EC patients. Expression of
CD95 in activated (either CD38+ or HLADR+) subsets
of CD8 cells was also higher in EC patients. Lastly, the
proportion of CD8 cells lacking CD28 expression was
also higher in EC patients (Fig. 5).
T-cell parameters associated with loss of immunological
control in EC patients
Of the 77 immunological variables selected by the PLS
model to differentiate between EC cases (EC patients show-
ing a significant CD4 count decline) and EC controls (EC
patients with a stable CD4 count), 12 presented statistically
significant differences between EC cases and EC controls
using the Mann–Whitney test. Interestingly, all of them
were variables with the highest coefficients (loadings) in the
Fig. 4 Dot plots showing the projection of the scores for LV2 and LV3 for each subject included in the study. Left: Scores for EC patients (open
circles) and HC subjects (black circles) obtained with the PLS-1 model. Right: Scores for EC controls (black circles) and EC cases (open circles)
obtained with the PLS-2 model. EC elite controller, HC healthy control, LV latent variable
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PLS model. The absolute value of the loading of each im-
munological variable in the PLS model is a measure of the
weight of the variable in the model and thus, the higher the
loading the higher the probability of significant differences
between the two groups (EC cases and EC controls). In fact,
for the entire set of 77 immunological variables selected by
the PLS model, there was a significant inverse correlation
between the absolute value of the loadings and the p values
obtained by the Mann–Whitney test (Additional file 6),
meaning that the higher the absolute value of the
loading, the higher the probability of a statistically
significant (p < 0.05) difference.
Moreover, using the Mann–Whitney U test, it was pos-
sible to evaluate those variables significantly different be-
tween EC cases and EC controls that were not selected by
the PLS model due to a numerical effect. This approach
allowed us to detect another nine immunological variables
with levels significantly different between EC cases and
EC controls. A complete list of immunological variables
significantly different by the Mann–Whitney test between
EC cases and EC controls is shown in Additional file 7.
Figure 6 shows levels for the most relevant variables
for EC cases and EC controls. Among CD4 subsets, EC
cases presented lower levels of CD38 expression on the
effector (CD45RA + CD27-CCR7-) subset of CD4 cells. In
contrast, the level of PD1 expression on total and on cen-
tral memory (CD45RA-CD27 + CCR7+) CD4 cells was
higher in EC cases compared to EC controls. Among CD8
T-cell subsets, compared to EC controls, EC cases showed
lower levels of naïve (CD45RA + CD27 + CCR7+) and of
Fig. 5 Box plots showing the levels of different CD4 (upper) and CD8 (lower) T-cell subsets in elite controller (EC) patients and in healthy subjects
(HC). The y-axis represents the percentages of cells. p values for the comparison between EC patients and HC (Mann–Whitney U test) are shown
in the graphs. EC elite controller, HC healthy control
Fig. 6 Box plots showing the levels of different CD4 (upper) and CD8 (lower) T-cell subsets in elite controller (EC) patients with a CD4 count
decline (EC cases) and in EC patients with a stable CD4 count (EC controls) during the follow-up period. The y-axis represents the percentages of
cells. p values are for the comparison between EC cases and EC controls (Mann–Whitney U test). EC elite controller
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RTE (naïve cells expressing CD31) subsets. In contrast,
the level of the effector (CD45RA + CD27-CCR7-) subset
was higher in EC cases as was the level of senescence
(CD28-CD57+) in total CD8 cells and in naïve CD8 cells.
Lastly, expression of CD95 in the effector subset of CD8
cells was lower in EC cases.
Overall, for those T-cell subsets that were significantly
different in EC patients with respect to HCs, the levels
for EC controls were intermediate between those found
in EC cases and HCs (Fig. 7). Thus, levels in EC controls
were more similar to levels in HCs than were levels in
EC cases, and for some of these subsets, the levels for
EC controls and HCs were not significantly different.
This was the case for levels of the CD45RA-CD27-
CCR7- subset of CD4 cells and for the levels of CD28 +
CD57- subset of CD8 cells (Fig. 7).
Discussion
The present study was designed to test the hypothesis that
perturbations in immunological parameters related to T-
cell homeostasis may be associated with CD4 T-cell loss in
EC patients maintaining long-term undetectable levels of
plasma HIV viremia. The main findings of our study are:
(1) there is an important perturbation of T-cell homeostasis
in EC patients despite long-term undetectable viremia; (2)
based on the T-cell parameters analyzed, a PLS-CM statis-
tical approach was able to discriminate and to predict, with
high sensitivity and specificity, EC patients experiencing im-
munological progression from those EC patients with a
stable CD4 count; and (3) immunological parameters asso-
ciated with the loss of CD4 T cells in EC patients included
mainly those related to CD8 T-cell homeostasis.
Despite the persistent control of HIV replication to un-
detectable levels, several alterations related to a state of sys-
temic inflammation have been recognized in ECs compared
to seronegative subjects and to HIV patients with cART-
mediated control of HIV replication [23–25], and this has
been associated with an increased rate of morbidity and
mortality in EC patients [24–26]. Our study demonstrates
that immunological alterations in EC patients are not lim-
ited to markers of systemic inflammation and extend to
several cellular markers of T-cell homeostasis. Although
the EC patients included in our study had maintained long-
term undetectable plasma HIV viremia, they clearly de-
parted from seronegative healthy subjects (HCs) regarding
the distribution of T-cell subsets. As many as 93 immuno-
logical variables were necessary to discriminate between EC
patients and HCs and many of these presented levels sig-
nificantly different between ECs and HCs, suggesting there
is an important perturbation of T-cell homeostasis in EC
patients despite long-term undetectable viremia.
Different processes involved in T-cell homeostasis were al-
tered in ECs compared to healthy subjects. Among them,
naïve and RTE subsets, stem cell memory subsets, regulatory
T cells, and expression of the costimulatory receptor CD28
were significantly decreased, whereas activation and expres-
sion of CD95 were significantly increased. Some of these per-
turbations have already been reported in different cohorts of
ECs, such as alterations in naïve/memory subsets [17, 19], in-
creased activation [15, 18, 27], increased senescence [27],
and decreased regulatory T cells [28]. However, EC cohorts
employed in these previous studies had varying degrees of
HIV-associated immune suppression (as reflected in CD4
counts) and different cutoffs of plasma viremia, meaning that
Fig. 7 Box plots showing the levels of different CD4 (upper) and CD8 (lower) T-cell subsets in healthy subjects (HCs), elite controller (EC) patients
with a stable CD4 count (Cont), and in EC patients with a CD4 count decline (Cas) during the follow-up period. The y-axis represents the percentages
of cells. Significant differences (p < 0.05) with respect to HCs are marked with an asterisk (*) and between the Cas and Cont groups of EC patients with
the ¶ symbol. EC elite controller, Cas EC case, Cont EC control, HC healthy control
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some alterations reported in these studies could be influ-
enced by CD4 counts [28] or low-level plasma HIV viremia
[27]. Since all EC patients included in our study had high
CD4 counts at the time of the immunophenotypic analysis,
our results demonstrate that perturbation of T-cell homeo-
stasis is already present in ECs from the early stages of HIV
disease. Moreover, our study is the first reporting alterations
in ECs of some important parameters of T-cell homeostasis
such as Tscm cells [29, 30]. Interestingly Tscm cells were di-
minished in both CD4 and CD8 T cells and thus, the poten-
tial to repopulate other subsets of memory cells [31] may be
compromised in ECs at early stages of infection.
The most relevant findings of our study are those
related to T-cell parameters associated with loss of im-
munological control in ECs. Using a set of 77 different
immunological variables, the PLS model was able to dis-
criminate, with high sensitivity and specificity, between
EC patients showing a significant CD4 decline (cases)
and those with stable CD4 counts (controls). The im-
munological variables were assessed when both groups
of EC patients presented similar high levels of CD4
counts (prior to CD4 T-cell loss in EC cases) and thus,
the differences found cannot be attributed to different
degrees of HIV-associated immune suppression, but ra-
ther they are characteristic of some EC subjects and
likely involved in the decline of CD4 T cells observed in
EC cases. Since no functional methods were employed
in this study, we can speculate only about the potential
mechanisms involved in the differences observed in the
extent of T-cell homeostasis disturbance between EC
cases and EC controls. Besides viral factors, such as the
higher levels of residual viral replication in EC cases
[10], several host-related factors could contribute to the
CD4 T-cell loss and T-cell homeostasis disturbance
observed in EC cases. Among them are defective thymic
function [17], lymphoid tissue fibrosis [32], genetic
variation in different genes related to immune response
[33, 34], and a cytokine-driven inflammatory milieu [35].
Interestingly, the two-sample non-parametric test
(Mann–Whitney U test) was not able to detect subtle
but important differences between cases and controls for
many of the immunological variables that were detected
by the PLS model. PLS-CM is an approach that is best
suited to extracting these differences employing latent
factors and building a predictive model in situations with
a small sample size and many predictive variables. In
agreement with this higher sensitivity of PLS modeling
to detect differences among a large panel of variables,
the immune parameters that had significant differences
by the two-sample test were those showing the highest
loadings in the PLS model.
The factors involved in the immunological progression
observed in some ECs that maintain virological control
are largely unknown and studies addressing this issue are
scarce, with only a few investigating potential associated
immunological factors [10, 15, 36, 37]. In some of these
studies, T-cell activation was shown to be associated with
disease progression in ECs using a cross-sectional design
[15, 36]. The other two studies addressing the association
of T-cell activation with CD4 evolution in EC patients and
using a longitudinal follow-up period similar to our study
[10, 37] found discordant results. One reported increased
activation associated with immunologic progression [10]
but the other did not [37]. Differences in the criteria used
to define immunological progression may explain the
discordant results. Moreover, both studies analyzed T-cell
activation when CD4 counts were significantly different
between EC patients showing immunological progression
and those maintaining stable CD4 counts, which is in
clear contrast with our study.
Our results show that several T-cell subsets showed
significant differences between EC cases and controls
and interestingly they were mainly related to CD8 cell
homeostasis. Naïve and RTE subsets of CD8 cells were
diminished in EC cases, suggesting either a defect in
thymic output or an increased rate of transition of naïve
cells to more differentiated subsets. Since a deficit in
thymic output would be reflected in the RTE subset of
both CD8 and CD4 compartments, our findings more
strongly support an increased rate of differentiation.
This, together with the finding of increased levels of ef-
fector CD8 cells in EC cases, supports the higher levels
of residual HIV replication in EC cases. Unfortunately,
we did not measure plasma HIV viremia with ultrasensi-
tive assays and thus, we can only speculate on this possi-
bility. However, in support of this hypothesis, previous
studies have found higher levels of residual viremia in
EC patients showing CD4 depletion [9, 10, 38]. Although
levels of effector CD8 cells were higher in EC cases,
CD8 T cells showed increased levels of the CD28-CD57
+ subset, a phenotype that has been associated with rep-
licative senescence [39]. CD8 T cells expressing this sen-
escent phenotype have lower cytotoxic potential [40, 41]
and produce high amounts of inflammatory cytokines
such as IL6 and TNFα [39], promoting an inflammatory
state that could contribute to the CD4 depletion
observed in EC cases. An interesting finding was that
naïve CD8 cells of EC cases also have increased levels of
senescence, suggesting that they have undergone an
antigen-independent expansion without differentiation
to memory cells in an attempt to maintain CD8 T-cell
homeostasis. Lastly, regarding alterations of CD4 T-cell
subsets, EC cases had increased levels of expression of
the cell exhaustion-associated marker PD1 in total CD4
cells and in central memory subset. Since overexpression
of PD1 has been associated with a lower ability to recon-
stitute CD4 T cells in HIV patients with cART-mediated
suppression of viral replication [42, 43], this increased
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expression of PD1 in EC cases could be another factor
contributing to CD4 depletion.
Finally, there are some caveats that deserve comment.
First, studies employing EC patients are very limited in
sample size given the very low frequency of this excep-
tional population of individuals among the whole popu-
lation of HIV-infected patients. However, in our study,
we addressed the potential bias of a small sample size by
studying a very homogeneous study population. Also, for
the data analyses we employed the PLS regression, which
is a statistical technique for performing multivariate cali-
bration, especially when there are more variables than
samples. Second, although the objective of our study had
no such scope, it could have been interesting to include
a group of HIV-normal progressors to assess whether
the underlying mechanisms of the loss of immune con-
trol in EC patients are comparable to those underlying
the non-immunological control in normal HIV+ pro-
gressors patients, as well as to evaluate the power of the
PLS model to discriminate between both phenomena.
Conclusions
In summary, the present study is the first to perform an
in-depth analysis of T-cell homeostasis disturbances in a
well-characterized cohort of ECs with long-term control
of HIV replication and showing different evolution of
CD4 counts. We used a PLS-CM statistical approach that
enabled us to detect subtle but important immunopheno-
type differences associated with the immunological pro-
gression. Overall, our results demonstrate the existence of
an important perturbation of T-cell homeostasis in EC pa-
tients despite long-term undetectable viremia. For those
EC patients experiencing immunological progression,
those disturbances are mainly related to CD8 T-cell
homeostasis. Our results may open new avenues for un-
derstanding the mechanisms underlying immunological
progression despite HIV replication control, suggesting
that active pathogenic mechanisms are still present in
some EC patients. These findings should be considered to
improve the clinical management of this exceptional
group of patients, and eventually in seeking a functional
cure through immune-based clinical trials.
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